Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) provide adequate glycemic control, weight reduction, low risk of hypoglycemia, and CV risk reduction. Their usage for type 2 DM (T2DM) is recommended mainly when hypoglycemia or weight gain should be considered, also, whenever initial therapy is failed. There are many recent updates in the treatment paradigm of T2DM. There are many types of GLP-1RAs, with a knowledge gap regarding switching between the different types. A Saudi task force gathered to develop an explicit, evidence-based consensus for switching between GLP-1RAs, when, why, and how? This article contains the expert panel’s recommendations as a contribution to complement the knowledge gap in this area from the national perspective. As an alternative to intensifying therapy, switching from one GLP-1RA to another has various advantages. Improvements in glycemic control, weight loss, adherence, and medications with established cardiovascular benefits are among them. Also, switching needs to be individualized upon many discussed factors like the dose of the previous GLP1-RA and gastrointestinal adverse effects. Discussion with patients about the why and how to switch is critical.
Highlights
Diabetes mellitus (DM) prevalence is rising quickly globally, and in Saudi Arabia (KSA) with its great impacts on both morbidity and mortality [1] [2].Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) provide effective glycemic control, weight reduction, low risk of hypoglycaemia and CV risk reduction
Among the several GLP-1RAs developed, exenatide, liraglutide, semaglutide, and dulaglutide are available in the Saudi market
Liraglutide, lixisenatide, oral semaglutide are used on a daily base, either once or twice as in the case of exenatide
Summary
Diabetes mellitus (DM) prevalence is rising quickly globally (by the year 2045 it is expected to become 9.9% with a total number of 629 Million), and in Saudi Arabia (KSA) with its great impacts on both morbidity and mortality [1] [2]. Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) provide effective glycemic control, weight reduction, low risk of hypoglycaemia and CV risk reduction Both the American Diabetes Association (ADA) guidelines and the ADA/European Association for the Study of Diabetes (EASD) consensus report, recommended their usage for type 2 DM (T2DM), when hypoglycemia or weight gain should be considered. Of all GLP-1RAs currently available, dulaglutide, liraglutide and once weekly semaglutide have demonstrated CV benefits, based on the results of several trials [9] [11] [12]. Their usage for patients with established atherosclerotic CV disease was recommended by the ADA. A Saudi task force, gathered to develop an explicit, evidence-based consensus for switching between GLP-1RAs, when, why and how? This article has the recommendations of this expert panel
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
